Common Stock, $0.001 par value
- Symbol
- SMTI
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Sanara MedTech Inc.
SMTINASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item Results 2.02 of Operations and Financial Condition. On August 11, 2026, Sanara MedTech Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.…
Press release in this filing
Sanara MedTech Inc. Reports Second Quarter 2026 Financial Results (Unaudited) →Company context
Sanara MedTech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets. The Company markets, distributes and develops surgical, wound and skin products for use by physicians and clinicians in hospitals, clinics and all post-acute care. Sanara’s products are primarily sold in the North American advanced wound care and surgical tissue repair markets. Sanara markets and distributes CellerateRX ® Surgical Activated Collagen ®, FORTIFY TRG ® Tissue Repair Graft and FORTIFY FLOWABLE ® Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN™ Verified Inductive Bone Matrix, ALLOCYTE ® Plus Advanced Viable Bone Matrix, BiFORM ® Bioactive Moldable Matrix, TEXAGEN ® Amniotic Membrane Allograft, and BIASURGE ® Advanced Surgical Solution to the surgical market. In addition, the following products are sold in the wound care market: BIAKŌS ® Antimicrobial Skin and Wound Cleanser, BIAKŌS ® Antimicrobial Wound Gel, and BIAKŌS ® Antimicrobial Skin and Wound Irrigation Solution. Sanara’s pipeline also contains potentially transformative product candidates for mitigation of opportunistic pathogens and biofilm, wound re-epithelialization and closure, necrotic tissue debridement and cell compatible substrates. The Company believes it has the ability to drive its pipeline from concept to preclinical a
Current securities
Registered securities in this filing
SANARA MEDTECH INC. · 8-K · Filed 2026-08-11
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item Results
2.02 of Operations and Financial Condition.
On
August 11, 2026, Sanara MedTech Inc. (the “Company”) issued a press release announcing its financial results for the quarter
ended June 30, 2026. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and
is incorporated by reference herein.
The
information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended,
or the Exchange Act, except as expressly set forth in such filing.
Filed exhibits (1)
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Sanara MedTech Inc. Reports Second Quarter 2026 Financial Results (Unaudited) FORT WORTH, TX, August 11, 2026 (GLOBE NEWSWIRE) - Sanara MedTech Inc. (“Sanara,” “Sanara MedTech,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today reported its financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Financial Summary (1) Net revenue increased 9% to $28.1 million, compared to $25.8 million in the second quarter of 2025. Gross profit of $26.2 million, or 93% of net revenue, compared to gross profit of $23.9 million, or 92% of net revenue, in the second quarter of 2025. Operating income of $1.8 million, compared to operating income of $2.5 million in the second quarter of 2025. Net loss from continuing operations of $0.4 million, or a loss of $0.05 per diluted share, compared to net income from continuing operations of $0.5 million, or $0.05 per diluted share, in the second quarter of 2025. Adju…
Open exhibit ↗